Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study

被引:65
作者
Boyd, Anita [1 ]
Stoodley, Paul [1 ,2 ]
Richards, David [1 ,3 ]
Hui, Rina [4 ,5 ,6 ]
Harnett, Paul [4 ,5 ,6 ]
Vo, Kim [1 ]
Marwick, Tom [7 ,8 ]
Thomas, Liza [1 ,3 ,5 ,6 ]
机构
[1] Westmead Private Cardiol, Westmead, NSW, Australia
[2] Western Sydney Univ, Sch Med, Campbelltown, NSW, Australia
[3] Univ New South Wales, Sydney South West Clin Sch, Sydney, NSW, Australia
[4] Westmead Hosp, Crown Princess Mary Canc Ctr, Westmead, NSW, Australia
[5] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[6] Univ Sydney, Westmead Clin Sch, Sydney, NSW, Australia
[7] Baker IDI, Melbourne, Vic, Australia
[8] Univ Tasmania, Hobart, Tas, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
GLOBAL LONGITUDINAL STRAIN; BREAST-CANCER; CARDIAC DYSFUNCTION; EUROPEAN ASSOCIATION; DEFORMATION INDEXES; EJECTION FRACTION; AMERICAN SOCIETY; HEART-FAILURE; FOLLOW-UP; CARDIOTOXICITY;
D O I
10.1371/journal.pone.0175544
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aims 2 dimensional (2D) strain analysis detects subclinical left ventricular (LV) systolic dysfunction. Our aim was to evaluate changes in LV systolic and diastolic function in breast cancer patients early after anthracycline chemotherapy, and to identify predisposing factors. Methods and results 140 patients were assessed by detailed echocardiography before and within seven days post treatment. LV ejection fraction (LVEF), global longitudinal strain (GLS), strain rate and radial and circumferential strain were assessed. Additionally, left atrial volumes and LV diastolic parameters were evaluated. LVEF although reduced after treatment, remained within the normal range (60 +/- 3% vs. 59 +/- 3%, p = 0.04). Triplane GLS was significantly reduced after treatment (-20.0 +/- 1.6% vs. -19.1 +/- 1.8%, p<0.001). Subclinical LV dysfunction (>11% reduction in GLS compared to before therapy) occurred in 22% (29/135). Impaired diastolic function grade significantly increased from 46% to 57% (p<0.001) after treatment. Furthermore, diastolic dysfunction was more common in the subgroup group with reduced systolic GLS compared to those without changes in GLS (30% vs. 11%; p = 0.04). No risk factors or clinical parameters were associated with the development of subclinical LV dysfunction; however the percentage change in early diastolic strain rate and the E velocity were independent predictors of >11% reduction in GLS. Conclusion Twenty two percent of patients had subclinical LV dysfunction by GLS, whilst none had cardiotoxicity defined by LVEF, demonstrating that GLS is more sensitive for detection of subclinical LV systolic dysfunction immediately after anthracycline therapy. Diastolic dysfunction increased, particularly in the group with reduced GLS, demonstrating the close pathophysiological relationship between systolic and diastolic function.
引用
收藏
页数:15
相关论文
共 33 条
[1]   Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy [J].
Cardinale, Daniela ;
Colombo, Alessandro ;
Bacchiani, Giulia ;
Tedeschi, Ines ;
Meroni, Carlo A. ;
Veglia, Fabrizio ;
Civelli, Maurizio ;
Lamantia, Giuseppina ;
Colombo, Nicola ;
Curigliano, Giuseppe ;
Fiorentini, Cesare ;
Cipolla, Carlo M. .
CIRCULATION, 2015, 131 (22) :1981-1988
[2]   Low to Moderate Dose Anthracycline-Based Chemotherapy Is Associated With Early Noninvasive Imaging Evidence of Subclinical Cardiovascular Disease [J].
Drafts, Brandon C. ;
Twomley, Katie M. ;
D'Agostino, Ralph, Jr. ;
Lawrence, Julia ;
Avis, Nancy ;
Ellis, Leslie R. ;
Thohan, Vinay ;
Jordan, Jennifer ;
Melin, Susan A. ;
Torti, Frank M. ;
Little, William C. ;
Hamilton, Craig A. ;
Hundley, W. Gregory .
JACC-CARDIOVASCULAR IMAGING, 2013, 6 (08) :877-885
[3]   Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity [J].
Ewer, MS ;
Lippman, SM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2900-2902
[4]   Head-to-Head Comparison of Global Longitudinal Strain Measurements among Nine Different Vendors The EACVI/ASE Inter-Vendor Comparison Study [J].
Farsalinos, Konstantinos E. ;
Daraban, Ana M. ;
Unlu, Serkan ;
Thomas, James D. ;
Badano, Luigi P. ;
Voigt, Jens-Uwe .
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2015, 28 (10) :1171-+
[5]   Left Ventricular Global Longitudinal Strain in HER-2+Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction [J].
Fei, Hong-wen ;
Ali, Mohammed T. ;
Tan, Timothy C. ;
Cheng, Kai-Hung ;
Salama, Laura ;
Hua, Lanqi ;
Zeng, Xin ;
Halpern, Elkan F. ;
Taghian, Alphonse ;
MacDonald, Shannon M. ;
Scherrer-Crosbie, Marielle .
ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES, 2016, 33 (04) :519-526
[6]   Anthracycline cardiotoxicity: From bench to bedside [J].
Gianni, Luca ;
Herman, Eugene H. ;
Lipshultz, Steven E. ;
Minotti, Giorgio ;
Sarvazyan, Narine ;
Sawyer, Douglas B. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3777-3784
[7]   Role of Anthracyclines in the Treatment of Early Breast Cancer [J].
Gianni, Luca ;
Norton, Larry ;
Wolmark, Norman ;
Suter, Thomas M. ;
Bonadonna, Gianni ;
Hortobagyi, Gabriel N. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4798-4808
[8]   Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol [J].
Gulati, Geeta ;
Heck, Siri Lagethon ;
Ree, Anne Hansen ;
Hoffmann, Pavel ;
Schulz-Menger, Jeanette ;
Fagerland, Morten W. ;
Gravdehaug, Berit ;
von Knobelsdorff-Brenkenhoff, Florian ;
Bratland, Ase ;
Storas, Tryggve H. ;
Hagve, Tor-Arne ;
Rosjo, Helge ;
Steine, Kjetil ;
Geisler, Jurgen ;
Omland, Torbjorn .
EUROPEAN HEART JOURNAL, 2016, 37 (21) :1671-1680
[9]   Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study [J].
Ho, Emily ;
Brown, Angela ;
Barrett, Patrick ;
Morgan, Roisin B. ;
King, Gerard ;
Kennedy, M. John ;
Murphy, Ross T. .
HEART, 2010, 96 (09) :701-707
[10]   Epirubicin: Is it like doxorubicin in breast cancer? A clinical review [J].
Khasraw, Mustafa ;
Bell, Richard ;
Dang, Chau .
BREAST, 2012, 21 (02) :142-149